Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedure related to recording of data according to the protocol * Previously FVIII treated (150 exposure days at the time of first dosing with turoctocog alfa) male patients with the diagnosis of severe and moderately severe haemophilia A (FVIII below or equal to 2%) * The decision to initiate treatment with commercially available turoctocog alfa has been made by the patient/parent and the patient's treating physician before and independently from the decision to include the patient in this study * A negative FVIII inhibitor test obtained not more than four weeks prior to first dosing with turoctocog alfa Exclusion Criteria: * Contraindications for use according to the approved product information text (US Package insert (PI), European Summary of Product Characteristics (SmPC), or corresponding local prescribing information) * Treatment with any investigational drug within 30 days prior to enrolment into the study * Previous participation in any clinical trial with turoctocog alfa * Treatment with other FVIII products after initiation of treatment with turoctocog alfa